Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000413143 | SCV000491271 | pathogenic | not provided | 2023-01-28 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect, including inactive or significantly reduced enzymatic activity (Muschol et al., 2004); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24816101, 21061399, 19099774, 25807448, 15146460, 29023963, 34813777, 31069529, 34047372, 34991944) |
Labcorp Genetics |
RCV000672002 | SCV002281415 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2024-03-07 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 191 of the SGSH protein (p.Gly191Arg). This variant is present in population databases (rs753666460, gnomAD 0.01%). This missense change has been observed in individuals with mucopolysaccharidosis type III (PMID: 15146460, 21061399, 23084433, 34813777). ClinVar contains an entry for this variant (Variation ID: 372781). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SGSH protein function. Experimental studies have shown that this missense change affects SGSH function (PMID: 15146460). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000672002 | SCV002813988 | likely pathogenic | Mucopolysaccharidosis, MPS-III-A | 2022-05-03 | criteria provided, single submitter | clinical testing | |
Intergen, |
RCV000672002 | SCV004015112 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2023-07-21 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000672002 | SCV004201088 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2024-01-03 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV000672002 | SCV005382435 | pathogenic | Mucopolysaccharidosis, MPS-III-A | 2023-05-20 | criteria provided, single submitter | clinical testing | The missense c.571G>A (p.Gly191Arg) variant in the SGSH gene has been observed in individuals with mucopolysaccharidosis type III. Experimental studies have shown that this missense change affects SGSH function (Muschol, Nicole et al.,2004). This variant is reported with the allele frequency (0.001%) in the gnomAD Exomes. It is submitted to ClinVar as Likely Pathogenic/ Pathogenic. The amino acid Glycine at position 191 is changed to a Arginine changing protein sequence and it might alter its composition and physico-chemical properties. The amino acid Glycine in SGSH is predicted as conserved by GERP++ and PhyloP across 100 vertebrates Multiple lines of computational evidence (Polyphen - Damaging, SIFT – Damaging and MutationTaster - Disease causing) predict a damaging effect on protein structure and function for this variant. For these reasons, this variant has been classified as Pathogenic. |
Counsyl | RCV000672002 | SCV000797053 | likely pathogenic | Mucopolysaccharidosis, MPS-III-A | 2018-01-15 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000672002 | SCV002095135 | likely pathogenic | Mucopolysaccharidosis, MPS-III-A | 2020-12-28 | no assertion criteria provided | clinical testing |